Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
38,294,063
-
Share change
-
+456,393
-
Total reported value
-
$890,928,000
-
Price per share
-
$23.28
-
Number of holders
-
61
-
Value change
-
+$7,677,776
-
Number of buys
-
25
-
Number of sells
-
29
Institutional Holders of KINNATE BIOPHARMA INC - COM (KNTE) as of Q2 2021
As of 30 Jun 2021,
KINNATE BIOPHARMA INC - COM (KNTE) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,294,063 shares.
The largest 10 holders included
Foresite Capital Management IV, LLC, ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Vida Ventures Advisors, LLC, FMR LLC, VIKING GLOBAL INVESTORS LP, VR Adviser, LLC, Logos Global Management LP, CITADEL ADVISORS LLC, and BlackRock Inc..
This page lists
61
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.